1. Scrip
  2. >>Business

Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles

Bidding War May Ensue

 
• By Andrew McConaghie

Biopharma M&A has had a quiet year so far but could heat up if rivals start vying for the biotech company.

Merck_New_Jersey
Merck & Co has enjoyed huge success with Keytruda, but needs to find ways to reduce its reliance on the blockbuster immunotherapy.

Merck & Co., Inc. is understood to be closing in on an $11bn deal to acquire Acceleron but pharma sector watchers are not ruling out a late bid from rival firms notably Bristol Myers Squibb.

A report from the Wall Street Journal on Monday identified Merck as the frontrunner in the race to acquire the Cambridge, MA based biotech company, rather than BMS as had...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

More from Scrip

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.